MNPR
Monopar Therapeutics
Next earnings Aug 10, 2026 · consensus $-0.65 EPS
Last earnings -0.7% on 2026-05-14
$87.68
▲ +0.06%$87.68▲ +175.46%
over 1Y
L $30.42EODHDH $102.05
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.1%
1W+27.7%
1M+35.8%
3M+62.1%
YTD+32.8%
1Y+175.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 19 analysts
Buy
Conservative balance sheet (liabilities/equity 0.02x).
Revenue (FY2025) $0.00 · FY2025
Monopar Therapeutics shows $0.00 in FY2025 revenue, and -10.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$9.13M | -$10.5M | -$8.83M | -$16.2M | -$16.7M |
| Net income | -$9.10M | -$10.5M | -$8.40M | -$15.6M | -$13.7M |
| Diluted EPS | -$0.73 | — | — | — | — |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$525M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.3%
FCF yield—
Quality & risk
ROIC (est.)-9.6%
Free cash flow—
Total debt—
Net cash$61.8M
Altman Z-Score121.71 safe
Piotroski F-Score3/7
Capital returns
Buyback yield6.0%
Dividend yield (est.)—
Shareholder yield6.0%
Shares Δ YoY+9.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-04-01). Worth a closer look.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-262026-06-26open ↗8-KPeriod ending 2026-06-222026-06-23open ↗8-KPeriod ending 2026-05-292026-05-29open ↗8-KPeriod ending 2026-05-192026-05-19open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗8-KPeriod ending 2026-05-142026-05-14open ↗SCHEDULE 13G/AFiling2026-05-13open ↗ARSPeriod ending 2025-12-312026-04-30open ↗DEFA14AFiling2026-04-30open ↗DEF 14APeriod ending 2026-06-222026-04-30open ↗8-KPeriod ending 2026-04-192026-04-20open ↗
Frequently asked
- Is Monopar Therapeutics (MNPR) a buy?
- MNPR currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.02x).
- What is Monopar Therapeutics's quality score?
- MNPR scores 52.179487179487175/100 (grade C-) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001645469, latest 10-Q filed 2026-05-14) · EODHD · as of 6/23/2026, 12:49:37 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.